Sajjad Hussain
Endocrinology, Diabetes & Metabolism · Manahawkin, NJNPI 1780672188
Payments from drug & device makers
Across 274 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$539
- Boehringer Ingelheim$374
- Medtronic$274
- Johnson & Johnson$208
- Dexcom, Inc.$193
- plus $795 from 19 others
What the payments were for
- Food & beverage$3,776100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 158 | $1,410 |
| AstraZeneca | 32 | $539 |
| Boehringer Ingelheim | 19 | $374 |
| Medtronic | 5 | $274 |
| Johnson & Johnson | 8 | $208 |
| Dexcom, Inc. | 11 | $193 |
| Lilly USA, LLC | 10 | $140 |
| Inari Medical, Inc. | 1 | $131 |
| Bayer | 3 | $103 |
| Abbott | 3 | $72 |
| Corcept Therapeutics | 5 | $65 |
| Amarin Pharma, Inc. | 4 | $59 |
| BD | 2 | $32 |
| Merck | 2 | $28 |
| Boston Scientific | 1 | $19 |
| Lifescan, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$263
- JARDIANCE$121
- INVOKANA$121
How this compares
$3,793 in reported general payments places this provider in the 60th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 406 | $601,683 |
| JardianceEmpagliflozin | 419 | $496,390 |
| FarxigaDapagliflozin Propanediol | 353 | $414,741 |
| RybelsusSemaglutide | 208 | $338,674 |
| TrulicityDulaglutide | 156 | $270,193 |
| MycapssaOctreotide Acetate | 13 | $171,882 |
| MounjaroTirzepatide | 67 | $111,544 |
| Bydureon BciseExenatide Microspheres | 61 | $103,085 |
| JanuviaSitagliptin Phosphate | 99 | $100,815 |
| TradjentaLinagliptin | 55 | $51,040 |
| InvokanaCanagliflozin | 22 | $33,480 |
| SynthroidLevothyroxine Sodium | 345 | $29,984 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $23,418 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $16,762 |
| Levothyroxine Sodium | 1,013 | $13,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,410 | $940,357614 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $374 | $560,044490 claims |
| AstraZenecaFarxiga | $539 | $414,741353 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $140 | $390,004245 claims |
| MerckJanuvia, Steglatro | $28 | $108,264111 claims |
| Johnson & JohnsonInvokana | $208 | $33,48022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Manahawkin
- Saima FarghaniManahawkin$36K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.